Special keys:

  • Alt + 1 - Home page;
  • Alt + v - ;
  • Alt + a - ;
  • Alt + c - ;
  • Alt + 1 ... Alt + 5 - Main menu navigation.

Key combinations given apply to Internet Explorer + Enter and Safari browser. If your browser is Firefox, use Alt + Shift + letter. Use combination Shift + Esc + letter for Opera, and Ctrl + Alt + letter or number for Mac'OS.

Biotechnology 

The Lithuanian biotechnology industry has been developing since the 1990s and is regarded as one of the most sophisticated in Central and Eastern Europe. It is estimated that the sector employs 700 people, including 160 R&D employees, while its total annual revenues exceed EUR 50 million. The success of the Lithuanian biotechnology industry has been reinforced by the return of Lithuanian scientists who had spent over a few years abroad.

However, the potential goes beyond this with a pool of a pool of 18,000 R&D researchers and specialists in Lithuania today. 15 research institutions carry out chemical and biochemical research on protein, enzymes and nucleic acid for pharmaceutical purposes. 16 institutions, including five major universities, train biotechnology and business specialists in cooperation with both domestic and foreign biotechnology companies. 

Industrial biotechnology

Lithuania has highly developed agricultural and forestry sectors. Industrial biotechnology became a rapidly growing sector of Lithuanian economy in the past decade, especially production of biofuel, and is going to continue growing in the years to come. Annually Lithuania produce excess of biomass that can be reproduced to biofuel:

  • around 1.0 million tons of surplus grain
  • more than 4.5 million tons of residual biomass and waste products from stockbreeding
  • more than 2.5 million m3 of forestry residues are formed during wood manufacturing

Success stories: Thermofisher, TEVA, Fermentas, SICOR Biotech, BIOK, Biocentras, Traidenis etc. More success stories


TEVA - Teva Pharmaceutical Industries (Israel) has acquired the Lithuanian enterprise of biotechnological pharmacy UAB Sicor Biotech in 2006. Now the company produces recombinant proteins for medical use (interferon alpha-2b, human growth hormone, granulocyte colonies stimulating factor, erythropoietin). It is the only factory of such a profile in Eastern and Central Europe. Company has a strong and very well-equipped research centre, developing technology for the production of recombinant proteins. The company has notably introduced a 25-35% cheaper but just as effective version of an existing medicine for treating cancer to the world market.